Biodexa Pharmaceuticals PLC
BDRX0.850USD
+0.012+1.42%
終値 07/17, 16:00（ET）15分遅れの株価
5.68B時価総額
--直近12ヶ月PER
詳細情報 Biodexa Pharmaceuticals PLC 企業名
Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.
企業情報
企業コードBDRX
会社名Biodexa Pharmaceuticals PLC
上場日Dec 08, 2014
設立日2014
最高経営責任者「CEO」Mr. Stephen A. Stamp
従業員数- -
証券種類Depository Receipt
決算期末Dec 08
本社所在地1 Caspian Point
都市ABINGDON
証券取引所NASDAQ Capital Market Consolidated
国United Kingdom
郵便番号CF10 4DQ
電話番号4401235888300
ウェブサイトhttps://www.biodexapharma.com/
企業コードBDRX
上場日Dec 08, 2014
設立日2014
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
Chief Executive Officer, Chief Financial Officer, Executive Director, Secretary
--
--
Dr. Sijmen (Sijmen) De Vries, M.D.
Dr. Sijmen (Sijmen) De Vries, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Controller
Group Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
収益内訳
通貨: GBP更新時刻: Sun, Jul 6
通貨: GBP更新時刻: Sun, Jul 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
データなし
地域別GBP
会社名
収益
比率
Belgium
381.00K
100.00%
事業別
地域別
データなし
株主
更新時刻: Fri, Jul 11
更新時刻: Fri, Jul 11
株主統計
種類
株主統計
株主統計
比率
Cavalry Fund I Management, LLC
3.47%
Brio Capital Management LLC
3.32%
Abbe (Richard)
0.48%
Bukwang Pharmaceutical Co., Ltd.
0.28%
Melior Pharmaceuticals I, Inc.
0.28%
Other
92.17%
株主統計
株主統計
比率
Cavalry Fund I Management, LLC
3.47%
Brio Capital Management LLC
3.32%
Abbe (Richard)
0.48%
Bukwang Pharmaceutical Co., Ltd.
0.28%
Melior Pharmaceuticals I, Inc.
0.28%
Other
92.17%
種類
株主統計
比率
Investment Advisor/Hedge Fund
7.03%
Corporation
0.69%
Individual Investor
0.48%
Investment Advisor
0.46%
Bank and Trust
0.20%
Venture Capital
0.11%
Hedge Fund
0.10%
Research Firm
0.01%
Other
90.93%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
36
447.86K
8.87%
+338.22K
2025Q1
38
272.70K
5.41%
+162.94K
2024Q4
37
258.63K
38.68%
+145.03K
2024Q3
39
166.61K
38.54%
+138.41K
2024Q2
36
78.92K
24.69%
+69.19K
2024Q1
28
31.04K
21.44%
+27.53K
2023Q4
30
32.82K
23.15%
+31.84K
2023Q3
21
574.00
6.29%
-2.15K
2023Q2
21
425.00
5.59%
-1.99K
2023Q1
22
183.00
8.18%
-2.20K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Cavalry Fund I Management, LLC
175.24K
3.47%
+175.24K
--
May 20, 2025
Brio Capital Management LLC
167.68K
3.32%
+110.57K
+193.59%
Nov 14, 2024
Abbe (Richard)
24.34K
0.48%
+24.34K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
14.18K
0.28%
+14.18K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
14.18K
0.28%
+14.18K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
14.18K
0.28%
+7.93K
+126.83%
Apr 01, 2024
GAMMA Investing LLC
1.43K
0.03%
+1.43K
--
Mar 31, 2025
UBS Switzerland AG
10.13K
0.2%
+10.13K
--
Mar 31, 2025
UBS Financial Services, Inc.
8.70K
0.17%
+1.65K
+23.41%
Mar 31, 2025
GS Capital Partners LLC
6.31K
0.12%
+6.31K
--
Apr 01, 2024
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
日付
種類
比率
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Sep 19, 2024
Merger
25<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Jun 26, 2023
Merger
80<1
Mar 16, 2023
Merger
4<1
Mar 16, 2023
Merger
4<1
詳細を見る
